IT 1208

Drug Profile

IT 1208

Alternative Names: IT-1208

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Kyowa Hakko Kirin
  • Developer IDAC Theranostics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research HIV infections

Most Recent Events

  • 17 May 2016 IDAC Theranostic plans a phase X trial for Solid tumours in Japan
  • 17 May 2016 IT 1208 will be licensed to ONO Pharmaceuticals to Ono Pharmacaceuticals signs a definitive agreement with IDAC Theranostics for the licensure of IT 1208
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top